Sobi, Inc. is an international biopharmaceutical company dedicated to rare diseases. Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants aged <1 year. RSV hospitalizations in preterm infants have been increasing since 2014 and often result in ICU admission and the need for mechanical ventilation.